photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer

Later Surgery for Advanced Pancreatic Cancer in Treatment Responders with Hepatic Lesions ?

Criteria for exclusion of patients from surgery for pancreatic cancer (ductal adenocarcinoma of the pancreas) include detection of distal metastases including those noted in the liver (also known as the hepatic organ).  However especially over the past decade, there have been a number of studies aimed at trying to discern whether liver lesions alone should […]

How many Patients with Pancreatic Cancer are Platinum Responders ?

Here in the Pancreatica Blog we have reported previous studies documenting patients with pancreatic cancer (ductal adenocarcinoma of the pancreas) with specific genetic characteristics such BRCA1 and BRCA2 mutations who have demonstrated robust treatment responses to DNA crosslinking agent “chemotherapy” such as platinum salts, PARP [poly ADP-ribose polymerase enzyme] inhibitors, and others.  By way of […]

FOLFIRINOX Induces a Full Pathological Response Leading to Resectability in Pancreatic Cancer

The four-drug FOLFIRINOX regimen represents a standard-of-care initial treatment for pancreatic cancer (ductal adenocarcinoma of the pancreas) despite substantive side-effects. Along with the gemcitabine plus Abraxane combination therapy it appears to offer survival advantage in pancreatic cancer over gemcitabine given alone. And increasingly, FOLFIRINOX is offered as therapy for locally advanced and “borderline resectable” pancreatic […]

Page 2 of 3712345...102030...Last »